Trial Profile
Bioequivalence Study Comparing the Pharmacokinetics and Glucodynamics of LY900014 U-200 Formulation With LY900014 U-100 Formulation in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin lispro (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 28 Mar 2018 Status changed from active, no longer recruiting to completed.
- 19 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Feb 2018 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018.